Compare JCE & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JCE | ZURA |
|---|---|---|
| Founded | 2007 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.8M | 252.9M |
| IPO Year | N/A | N/A |
| Metric | JCE | ZURA |
|---|---|---|
| Price | $16.03 | $5.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.38 |
| AVG Volume (30 Days) | 49.7K | ★ 934.6K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 9.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.64 | $0.97 |
| 52 Week High | $14.28 | $6.63 |
| Indicator | JCE | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 49.65 | 60.68 |
| Support Level | $15.88 | $5.96 |
| Resistance Level | $16.22 | $6.62 |
| Average True Range (ATR) | 0.21 | 0.61 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 50.98 | 70.90 |
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.